Nadunolimab is a human monoclonal IgG1 antibody targeting IL1RAP. Nadunolimab blocks IL-1α and IL-1β signaling and triggering antibody-dependent cellular cytotoxicity. Nadunolimab can be used in research of cancer.
性状
Liquid
IC50 & Target[1][2]
IL-1α IL-1β
体外研究(In Vitro)
Nadunolimab (20 μg/mL; 30 min and 1 h; A549 cells and BxPC3 cells) reduces IL-1α-induced release of pro-infamma tory cytokines and chemokines, including IL-1β, IL-6 TNF-α and MIP-1α, and CXCL1. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Nadunolimab (10 mg/kg; i.p.; twice on day 1 and thereafter twice weekly; nude BALB/c mice with LU2503 or MC38 tumors) improves the anti?tumor efficacy of chemotherapy and blocks both murine IL-1α and IL-1β signaling. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.